IPC Highlights IP 2026 Standards at Pharma Conclave in Uttarakhand

Participants received practical guidance on applying these standards in day-to-day pharmaceutical manufacturing and testing activities.

The Indian Pharmacopoeia Commission (IPC), functioning under the Ministry of Health and Family Welfare, brought together pharmaceutical industry leaders, regulators and scientific experts at a special conclave in Haridwar to discuss the implementation of Indian Pharmacopoeia (IP) 2026 and strengthen quality compliance across the sector.

Organized in collaboration with the Association of Devbhumi Pharma Industries (ADPI) and affiliated pharmaceutical associations of Uttarakhand, the event focused on helping manufacturers better understand the latest pharmacopoeial standards and their role in ensuring the quality, safety and effectiveness of medicines.

Uttarakhand's Pharma Sector Takes Centre Stage

Uttarakhand has actively adopted the Indian Pharmacopoeia and Indian Pharmacopoeia Reference Substances in pharmaceutical production and quality testing processes. The programme was designed to support pharmaceutical manufacturers, testing laboratories and quality professionals in understanding updated requirements under IP 2026. By encouraging wider adoption of these standards, the initiative seeks to strengthen quality assurance systems across the industry and support compliance with national regulatory expectations. Representatives from pharmaceutical companies, quality control and quality assurance departments, analytical laboratories and regulatory bodies participated in the discussions.

Experts Discuss New Developments in IP 2026

The inaugural session began with a welcome address by ADPI Chairman Sandeep Jain, who stressed the value of close cooperation between industry stakeholders and standard-setting organizations in improving pharmaceutical quality systems.

The gathering was also addressed by Sidharth Sahai Malhotra, Assistant Drugs Controller (India), CDSCO Dehradun, and Tajber Singh, Drug Controller and State Licensing Authority of Uttarakhand. Both speakers highlighted the importance of pharmacopoeial standards in supporting regulatory compliance and protecting public health.

Delivering the chief guest address, Dr. V. Kalaiselvan, Secretary-cum-Scientific Director of IPC, spoke about the growing significance of the Indian Pharmacopoeia in setting scientifically validated quality benchmarks for medicines. He outlined several advancements incorporated in IP 2026 and emphasized the role of industry participation in ensuring effective implementation of the updated standards.

Interactive Sessions Focus on Quality Compliance

The conclave featured detailed technical sessions covering recent developments in pharmacopoeial standards, reference substances, microbiological quality requirements, analytical investigations, biological standards and quality management systems.

Participants received practical guidance on applying these standards in day-to-day pharmaceutical manufacturing and testing activities. A dedicated interaction session allowed industry representatives to engage directly with IPC scientists and seek clarification on technical and regulatory matters related to IP 2026.

The discussions reflected strong interest from the pharmaceutical sector in aligning with evolving quality requirements and strengthening manufacturing practices. The event concluded with a networking session that encouraged continued dialogue among regulators, manufacturers and scientific experts on improving pharmaceutical quality and compliance across Uttarakhand and the wider Indian pharmaceutical industry.